The Correlation of Maternal Uric Acid Concentration with Small-for-Gestational-Age Fetuses in Normotensive Pregnant Women

Yoichiro Akahori   Hisashi Masuyama   Yuji Hiramatsu

Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Key Words
Blood pressure · Creatinine · Small for gestational age · Uric acid

Abstract
Aim: Elevated maternal serum uric acid is associated with small-for-gestational-age (SGA) fetuses. We investigated whether uric acid concentrations in normotensive pregnant women are correlated with fetal growth and related to kidney function. Methods: We carried out a case-control study using 40 patients who delivered SGA fetuses identified from the perinatal database and 80 patients who delivered appropriate-for-gestational-age (AGA) fetuses as the controls at Okayama University Hospital. Blood pressure, serum uric acid and creatinine level were measured in the patients’ third trimester. Results: Maternal serum uric acid (p = 0.0003) and creatinine (p < 0.0001) concentrations, as well as systolic and diastolic blood pressures (p = 0.014 and 0.037, respectively), were significantly increased in the SGA group. There was a strong negative correlation between serum uric acid levels and birth weights (r = −0.59; p = 0.006) and a significant positive correlation between maternal serum uric acid and creatinine levels (r = 0.43; p < 0.05) in cases of severe SGA (<5th percentile). Multiple linear regression analysis indicated that uric acid is an independent risk factor for SGA. Conclusions: Increasing maternal uric acid concentrations were associated with slightly impaired kidney function and SGA in normotensive pregnant women.

Introduction

During pregnancy, circulating uric acid levels are regulated by alterations in renal handling. Maternal serum uric acid levels decrease by 25–35% during the first trimester due to an increase in glomerular filtration rate and a decrease in reabsorption in the proximal tubule. There is a subsequent rise to prepregnancy levels near term, which is related to a decrease in uric acid clearance due to postsecretory reabsorption [1–4].

Hyperuricemia in pregnancy is associated with adverse fetal outcome and preeclampsia. Uric acid directly inhibits amino acid transfer in the placenta and suppresses fetal growth [2]. Elevated levels of uric acid may have a proliferative and proinflammatory effect on the small blood vessels of the placenta, resulting in small-for-gestational-age (SGA) fetuses [5]. Uric acid stimulates the production of vasoconstrictors and inflammatory agents, re-
duce nitric oxide production, and increases thrombox-
ane generation in vascular smooth muscle cells [6–9].
Thus, hyperuricemia is strongly associated with endo-
thelial cell dysfunction, and elevated serum uric acid levels
usually precede hypertension.

In patients with preeclampsia, the association between
maternal uric acid levels and birth weights has been in-
vestigated [10, 11]. Furthermore, in normotensive preg-
nant women, uric acid concentrations in the second tri-
mester correlated with insulin resistance and lower birth
weights [12]. Presently, there are no reports describing the
association between hyperuricemia and birth weight
with respect to renal functions.

In this study, we related uric acid concentrations in the
third trimester to birth weight among normotensive
pregnant women. We evaluated the association between
maternal serum uric acid levels and intrauterine fetal
growth in relation to serum creatinine levels as a measure of
maternal renal function.

Subjects and Methods

Study Design

We carried out a case-control study using 40 patients who de-
ivered SGA fetuses (SGA group) identified from the perinatal
database from 2005 to 2009, and 80 patients who delivered appro-
riate-for-gestational-age (AGA) fetuses as the controls (AGA
group) in 2009 at the Okayama University Hospital, who were
consecutive subjects in each of the groups. Blood pressure was
recorded as the average of three measurements. Diastolic blood
pressure was determined by a mercury sphygmomanometer
using the fifth Korotkoff sound after a 5-min rest in sitting position
when the patients visited our outpatient office during the morn-
ing. Pregnant women were normotensive, defined as a systolic
blood pressure <140 mm Hg and a diastolic blood pressure <90
mm Hg. According to Japanese standards, SGA was defined as a
birth weight <10th percentile, severe SGA was <5th percentile,
and AGA was >10th but <90th percentile. Exclusion criteria were:
SGA due to congenital abnormality, chromosomal abnormality,
maternal complications including diabetes mellitus and collagen
diseases, multiple birth, and umbilical cord factors; maternal use
of alcohol and nicotine; and preterm birth. There were no preg-
nant women with either AGA or SGA who developed preeclamp-
sia or hypertension during labor or after delivery.

Baseline demographic information collected from the data-
based included: maternal height, weight before pregnancy, weight
at the time of delivery, weight gain during pregnancy, body mass
index (BMI) before pregnancy, maternal blood pressure, gesta-
tional age (weeks) at delivery, the newborn's gender, birth weight
(grams; percentile as a measure of the severity of SGA), Apgar
score, and placental weight.

This study was approved by the Institutional Ethical Review
Board of Okayama University Hospital (project No. 186, June 21st,
2004), and all subjects gave their informed consent.

Laboratory Analyses

Blood was collected in the third trimester before the start of
labor. Serum samples were immediately prepared by centrifugal
separation. Serum uric acid (Sino-test Co., Tokyo, Japan) and cre-
atinine (Mizuho Medy Co., Ltd., Saga, Japan) levels were mea-
ured using colorimetric assay kits according to the manufactur-
er’s instructions. The coefficients of variance were 6 and 8%, re-
spectively.

Statistical Analysis

Data are presented as means ± SD. All comparisons between
the SGA and AGA groups were carried out using the Mann-Whit-
ney U test, except for gender and the proportion of primigravidas,
which were analyzed with the χ² test. Correlation between vari-
ables was conducted with Spearman’s rank correlation. Multiple
linear regression analysis was performed to determine which fac-
tors were significantly and independently correlated with severe
SGA. The following parameters were included in the model: uric
acid concentrations, placental weights, mean blood pressure, and
weight gains during pregnancy. A p value of <0.05 was considered
significant. Statistical analyses were conducted using JMP statis-
tical discovery software (SAS Institute, Cary, N.C., USA).

Results

Patient Characteristics

There were no significant differences in maternal age,
the proportion of primigravidas, height, weight and BMI
before pregnancy, and weight gain during pregnancy, be-
tween the SGA and AGA groups. The mean birth weight
(AGA: 2,913 ± 282 g; SGA: 2,304 ± 271 g; p < 0.0001)
and placental weight (AGA: 570 ± 95 g; SGA: 420 ± 58 g;
p < 0.0001) were significantly lower in the SGA group,
although the mean gestational age at delivery (AGA: 38.0
± 0.8 weeks; SGA: 38.6 ± 1.33 weeks; p = 0.02) was sig-
nificantly higher. Mean systolic (AGA: 108.6 ± 13.1 mm
Hg; SGA: 115.2 ± 10.8 mm Hg; p = 0.014) and diastolic
blood pressures (AGA: 65.8 ± 10.6 mm Hg; SGA: 70.1 ±
9.6 mm Hg; p = 0.037), and the mean blood pressure (i.e.
diastolic pressure + 1/3(systolic pressure – diastolic pres-
sure); AGA: 80.0 ± 10.9 mm Hg; SGA: 85.1 ± 9.5 mm
Hg; p = 0.016) were significantly higher in the SGA group,
although they remained within the normal range (table 1).

The incidence of cesarean section in pregnant women
with AGA was high compared to those with SGA (93.8 vs.
55%). Delivery by cesarean section allowed us to obtain
clinical laboratory data including creatinine and uric acid
levels, because normal pregnant women who vaginally
deliver do not routinely receive blood examinations for
renal and liver functions in our hospital. The method of
selection for pregnant women with AGA might have af-
fected the average of gestational weeks at delivery. In the SGA group, 14 elective cesarean sections were planned due to previous myomectomy, previous Jones and Jones operation, breech presentation or previous cesarean section, and 8 emergent operations were performed due to nonreassuring fetal status. In the AGA group, 75 elective cesarean sections were planned due to breech presentation, previous myomectomy or previous cesarean section. However, there was no significant difference in gestational age at sampling and all samples in both groups were obtained before labor onset.

**Maternal Uric Acid Levels**

The mean gestational age at collection of serum samples was not significantly different between the two groups (AGA: 35.9 ± 1.4 weeks; SGA: 36.3 ± 1.9 weeks; table 1). The mean maternal serum uric acid level (SGA: 0.29 ± 0.07 mmol/l; AGA: 0.24 ± 0.05 mmol/l; p = 0.0003; fig. 1a) and maternal serum creatinine level (SGA: 48.3 ± 7.7 μmol/l; AGA: 42.3 ± 6.6 μmol/l; p < 0.0001; fig. 1b) were significantly higher in the SGA group than in the AGA group. However, their fluctuations were within the reference range for nonpregnant women. The mean uric acid level of SGA at umbilical cord blood (0.30 ± 0.07 mmol/l, n = 10) was significantly increased compared with AGA (0.25 ± 0.08 mmol/l, n = 21) (p = 0.005).

**Maternal Uric Acid Levels and Severe SGA**

Twenty cases of SGA were diagnosed as severe with a birth weight <5th percentile and the mean maternal serum uric acid level and creatinine level were 0.31 ± 0.08 mmol/l and 47.7 ± 9.4 mmol/l, respectively. In the severe SGA group, there was a significant negative correlation between birth weight percentile and maternal serum uric acid levels (r = –0.59; p = 0.006; fig. 2a), and a significant positive correlation between maternal serum uric acid and creatinine levels (r = 0.43; p < 0.05; fig. 2b). There

---

**Table 1. Patients’ characteristics**

<table>
<thead>
<tr>
<th></th>
<th>AGA (n = 80)</th>
<th>SGA (n = 40)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>31.4 ± 4.76</td>
<td>31.1 ± 5.49</td>
<td>ns</td>
</tr>
<tr>
<td>Primipara/multipara</td>
<td>54/26</td>
<td>27/13</td>
<td>ns</td>
</tr>
<tr>
<td>Height, cm</td>
<td>157.4 ± 5.6</td>
<td>158.0 ± 4.19</td>
<td>ns</td>
</tr>
<tr>
<td>Body weight (pre-pregnancy), kg</td>
<td>52.4 ± 9.0</td>
<td>51.1 ± 7.2</td>
<td>ns</td>
</tr>
<tr>
<td>BMI</td>
<td>21.1 ± 3.5</td>
<td>20.3 ± 2.4</td>
<td>ns</td>
</tr>
<tr>
<td>Body weight gain during pregnancy, kg</td>
<td>8.9 ± 3.8</td>
<td>7.3 ± 4.2</td>
<td>ns</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>108.6 ± 13.1</td>
<td>115.2 ± 10.8</td>
<td>0.014</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>65.8 ± 10.6</td>
<td>70.0 ± 9.6</td>
<td>0.037</td>
</tr>
<tr>
<td>Mean blood pressure, mm Hg</td>
<td>80.0 ± 10.9</td>
<td>85.1 ± 9.5</td>
<td>0.016</td>
</tr>
<tr>
<td>Gestational age at blood sampling, weeks</td>
<td>35.9 ± 1.4</td>
<td>36.3 ± 1.9</td>
<td>ns</td>
</tr>
<tr>
<td>Placenta, g</td>
<td>570 ± 95</td>
<td>420 ± 58</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Gestational age at delivery, weeks</td>
<td>38.0 ± 0.8</td>
<td>38.6 ± 1.33</td>
<td>0.02</td>
</tr>
<tr>
<td>Gender, male/female</td>
<td>40/40</td>
<td>21/19</td>
<td>ns</td>
</tr>
<tr>
<td>Birth weight, g</td>
<td>2,913 ± 282</td>
<td>2,304 ± 271</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Birth weight, percentile</td>
<td>46.8 ± 23.0</td>
<td>4.5 ± 2.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Height at birth, cm</td>
<td>48.3 ± 1.8</td>
<td>46.8 ± 2.2</td>
<td>0.0005</td>
</tr>
</tbody>
</table>

Unless noted, values are the mean ± SD. ns = Not significant. Statistical analysis was conducted by Mann-Whitney’s U test except for ‘Primipara/multipara’ and ‘Gender’ which were conducted by χ² test.
were no significant correlations between birth weight percentile and maternal serum creatinine levels ($r = -0.39$; fig. 2c) and between birth weight percentile and the systolic, diastolic, and mean blood pressures (data not shown). There were no significant correlations among each factor examined here in the mild SGA group and in the control group. By forward selection method, uric acid, placental weight, mean blood pressure and weight gain were chosen as the independent factors, but creatinine was not chosen. Multiple linear regression analysis using maternal serum uric acid levels, maternal mean blood pressures, placental weights, and maternal weight gains during pregnancy as continuous variables, and birth weight percentile as the objective variable (table 2) indicated that maternal uric acid levels and maternal weight gain during pregnancy were associated with severe SGA. We also analyzed systolic and diastolic blood pressure as continuous variables, but they were not associated with severe SGA.

### Discussion

In this study, we evaluated the relationship between maternal serum uric acid levels and birth weights in normotensive pregnant women. We found elevated maternal uric acid levels in the third trimester in women diagnosed with SGA, but a significant negative correlation between maternal uric acid levels and birth weight percentiles in cases of severe SGA. The associations between hyperuricemia with preeclampsia and SGA [10, 11] and hyperuricemia with insulin resistance and lower birth weight in normotensive women in midpregnancy have previously been reported [12]. These data suggest that elevated uric acid concentrations might have a direct or indirect effect on fetal growth.

Elevated uric acid levels were negatively correlated with fetal growth. However, the variations in uric acid levels were within the reference range measured in healthy human serum (0.12–0.39 mmol/l). Hyperuricemia is associated with components of metabolic syndrome. The difference in serum uric acid levels between patients with metabolic syndrome and controls can be as low as 0.03–0.06 mmol/l [13–15], and the average serum uric acid concentration of patients with metabolic syndrome is 0.35 mmol/l [15]. These data indicate that the fluctuations in serum uric acid levels between the SGA (0.29 mmol/l) and the AGA (0.24 mmol/l) group in our study are similar to the difference between metabolic syndrome and normal controls, suggesting that this variation might be significant for fetal growth.

We used serum creatinine concentrations to evaluate maternal renal function. Information describing renal
functions during normal pregnancy is limited. Renal function in nonpregnant women is assessed using a predictive equation developed from the Modification of Diet in Renal Disease study, which calculates an estimated glomerular filtration rate [16]. However, this calculation underestimates the GFR in healthy pregnant women and those with preeclampsia [17]. In these cases, maternal serum creatinine levels and creatinine clearance may provide a more accurate assessment of renal function [17]. We found a slight increase in maternal serum creatinine in the SGA group, which implied that renal function was deteriorating. As maternal serum creatinine and uric acid levels showed a positive correlation, inferior maternal renal function in the SGA group may have caused the increase in serum uric acid concentrations, or the clearances of uric acid and creatinine from the circulation may be affected by similar mechanisms at the same time in the SGA group. Because we have no additional data about the relationship between uric acid and other markers for renal function, further analysis is required to investigate the relationship between serum uric acid levels and renal function during pregnancy.

In SGA patients, maternal blood pressure was significantly elevated, probably in association with the higher uric acid levels. Hyperuricemia is known to induce vascular smooth muscle cell proliferation and inflammation, resulting in increased blood pressure [5, 7–9]. The fluctuations in maternal blood pressure were all within the normal range, therefore the clinical implications of our findings are unknown. Increased levels of serum uric acid may damage the placental vasculature and result in preeclampsia [6]. Furthermore, elevated serum uric acid in pregnant women is associated with SGA, possibly due to a reduction in placental uptake of amino acids [18]. The higher maternal uric acid levels in our SGA patients may be involved in the mechanisms resulting in reduced fetal growth.

Uric acid is the end product of purine metabolism, and it is primarily excreted through the kidneys. In serum, the concentration of uric acid in healthy individuals is maintained at 0.35 mmol/l or less; hyperuricemia is defined as a serum uric acid concentration of >0.35 mmol/l [19]. When hyperuricemia develops, cardiovascular disease, renal failure, gout and urinary stones, metabolic syndrome, and insulin resistance can occur [20, 21]. Furthermore, uric acid passes easily through the placenta by simple diffusion [22]. We observed that the mean concentration of uric acid in placental blood were significantly different between the two groups. According to the Barker hypothesis, in utero exposure to hyperuricemia might alter developmental programming resulting in a decreased number of nephrons and a predisposition to insulin resistance [12, 23, 24]. In future, this interesting aspect should be further investigated.

In this study, SGA occurred in women with slightly elevated blood pressure and lower renal functions that were within the normal nonpregnant range; the characteristics of the group were not consistent with the diagnostic criteria for preeclampsia. We conclude that slightly impaired kidney function might result in increased maternal uric acid, which was associated with SGA in normotensive women. Our data also suggested that uric acid level might a potential marker for slightly impaired kidney function and SGA in normotensive pregnant women for daily clinical obstetric management.

**Acknowledgement**

This work was supported in part by research grants (17591739) from the Ministry of Education, Science and Culture of Japan.

**References**


